EMA Verdict Due On Vertex/CRISPR’s Gene Editing Therapy & Reata’s Omaveloxolone

The European Medicines Agency’s human medicines committee is meeting to decide whether to recommend the pan-EU approval of eight new medicines, including the CRISPR/Cas9 genome-edited cell therapy, exa-cel.